Company intelligence / Profile preview
Jianmin Pharmaceutical Group
Wuhan, Hubei, Chinawhjm.com ↗
- Ownership
- Private
- Development stage
- Commercial
01
Overview
Jianmin has several approved drugs—primarily herbal/traditional Chinese medicine—for pediatric fever ("Calculus bovis Infantile Umbilical Paste"), stroke ("NiuHuangQingXin Pill"), chronic gastritis ("Qirui Weishu Capsule"), acute bronchitis ("Xiaoer Zibei Xuanfei Syrup"). One product for nonerosive gastro-esophageal reflux disease is in Phase 3 trials. The company continues to expand its portfolio into oncology and cardiovascular areas with new launches as recently as 2023.
- Therapeutic areas
- Infectious DiseasesOncologyEndocrinologyOtherGastroenterologyCardiovascularNeurologyWomen's Health
- Modalities
- Herbal medicineChemical drugs
- Industry
- Biotech
02
Drug pipeline
26 assets25 more assets in the full pipeline.
03
Partnerships
Over ten partnerships with leading medical research institutions for joint R&D projects as of 2023
Beyond the preview
Go deeper on Jianmin Pharmaceutical Group.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Jianmin Pharmaceutical Group.